We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Microbiologics Acquires Phthisis Diagnostics, New Direction Exhibited at Current Meeting of the Association for Molecular Pathology

By LabMedica International staff writers
Posted on 11 Nov 2013
Phthisis Diagnostics (Charlottesville, VA, USA) has announced its acquisition by Microbiologics (St. More...
Cloud, MN, USA) to establish Phthisis’ technology as the foundation for a new division at Microbiologics.

Pthisis’ patented “G-Sphere” molecular standards product line will be the foundation for Microbiologics’ launch into molecular products and for the new division it is forming. G-Sphere standards are synthetic genes that provide easy-to-use, safe, stable, consistent, and abundant controls for virtually any organism or molecular assay. Currently, Microbiologics produces an array of lyophilized microorganism products in convenient, ready-to-use formats for quality control of microbiological testing.

Crystal Icenhour, PhD, adjunct assistant professor of infectious diseases at Duke University Medical Center, and President and Chief Science Officer at Phthisis since 2006, along with her research team, created the new technology. She will serve as an advisor with Microbiologics during the adoption of Phthisis’ technology and development of their new division. “We introduced this product line about a year ago to provide much needed quality control standards to molecular laboratories. I am pleased that this longer established company will have the structure to take these products much further than our smaller company could have,” said Prof. Icenhour.

Brad Goskowicz, Microbiologics CEO, commented, “These innovative molecular standards will lay the foundation for Microbiologics to design and launch a broad collection of molecular products and custom services. It will expand our range of biomaterials to include viruses and other hard to grow microorganisms.”

Microbiologics is adding Brian Beck, PhD in bacteriology, to its senior management team as Vice President of Molecular Products and Services. Dr. Beck has spent the last ten years at ATCC in Virginia where he managed the Microbiology Collection and Associated BioServices. “I’m quite excited to extend what Microbiologics has done with their culture business and bring that same practical, user-friendly format to the molecular diagnostic business,” said Dr. Beck.

To commence their new initiative, Microbiologics is exhibiting at the Association for Molecular Pathology (AMP) annual meeting, November 14-16, 2013, Phoenix (Arizona, USA).

Related Links:

Phthisis Diagnostics
Microbiologics



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.